Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 426

Similar articles for PubMed (Select 22944197)

1.

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.

Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.

Urol Oncol. 2013 Nov;31(8):1770-9. doi: 10.1016/j.urolonc.2012.06.015. Epub 2012 Sep 1.

PMID:
22944197
2.

HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression.

He P, Liang J, Shao T, Guo Y, Hou Y, Li Y.

Int J Clin Exp Med. 2015 Apr 15;8(4):6510-6. eCollection 2015.

3.

Nucleolar Translocation of Histone Deacetylase 2 Is Involved in Regulation of Transcriptional Silencing in the Cat Germinal Vesicle.

Lee PC, Wildt DE, Comizzoli P.

Biol Reprod. 2015 Jun 24. pii: biolreprod.115.129106. [Epub ahead of print]

4.

208 Histone deacetylase (HDAC) I catalytic core Asp-His charge relay system is altered by HDAC inhibitors: atomistic simulation studies.

Omotuyi IO, Olusanya O.

J Biomol Struct Dyn. 2015 May;33 Suppl 1:140. doi: 10.1080/07391102.2015.1038139. No abstract available.

PMID:
26103418
5.

Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers.

Chun SG, Park H, Pandita RK, Horikoshi N, Pandita TK, Schwartz DL, Yordy JS.

Am J Cancer Res. 2015 Mar 15;5(4):1337-52. eCollection 2015.

6.

4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.

Mahal K, Kahlen P, Biersack B, Schobert R.

Exp Cell Res. 2015 Jun 19. pii: S0014-4827(15)30017-3. doi: 10.1016/j.yexcr.2015.06.008. [Epub ahead of print]

PMID:
26101158
7.

Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.

Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER.

Invest New Drugs. 2015 Jun 20. [Epub ahead of print]

PMID:
26091915
8.

Histone deacetylase 5 regulates the inflammatory response of macrophages.

Poralla L, Stroh T, Erben U, Sittig M, Liebig S, Siegmund B, Glauben R.

J Cell Mol Med. 2015 Jun 8. doi: 10.1111/jcmm.12595. [Epub ahead of print]

PMID:
26059794
9.

H3K27 demethylation at the proviral promoter sensitizes latent HIV to the effects of vorinostat in ex-vivo cultures of resting CD4+ T cells.

Tripathy MK, McManamy ME, Burch BD, Archin NM, Margolis DM.

J Virol. 2015 Jun 3. pii: JVI.00572-15. [Epub ahead of print]

PMID:
26041287
10.

Assessment of Tissue Level of Histone Deactylase-2 (HDAC-2) in Patients With Mycosis Fungoides.

El Tawdy A, Amin I, Abdel Hay R, Rashed L, Gad Z.

J Cutan Med Surg. 2015 Jun 1. pii: 1203475415589055. [Epub ahead of print]

PMID:
26033703
11.

Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue.

Cantley MD, Dharmapatni AA, Algate K, Crotti TN, Bartold PM, Haynes DR.

J Periodontal Res. 2015 Jun 2. doi: 10.1111/jre.12290. [Epub ahead of print]

PMID:
26031835
12.

HDAC8: a multifaceted target for therapeutic interventions.

Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M.

Trends Pharmacol Sci. 2015 Jul;36(7):481-92. doi: 10.1016/j.tips.2015.04.013. Epub 2015 May 23. Review.

13.

Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.

Geron L, Borges KS, Andrade AF, Suazo VK, Scrideli CA, Tone LG.

Neurol Res. 2015 Aug;37(8):703-11. doi: 10.1179/1743132815Y.0000000048. Epub 2015 May 22.

PMID:
26000978
14.

miR-2861 as novel HDAC5 inhibitor in CHO cells enhances productivity while maintaining product quality.

Fischer S, Paul AJ, Wagner A, Mathias S, Geiss M, Schandock F, Domnowski M, Zimmermann J, Handrick R, Hesse F, Otte K.

Biotechnol Bioeng. 2015 May 21. doi: 10.1002/bit.25626. [Epub ahead of print]

PMID:
25997799
15.

The ALKYLATING-HDAC INHIBITION FUSION PRINCIPLE: TAKING CHEMOTHERAPY to the NEXT LEVEL WITH the FIRST in CLASS MOLECULE EDO-S101.

Mehrling T, Chen Y.

Anticancer Agents Med Chem. 2015 May 17. [Epub ahead of print]

PMID:
25980817
16.

Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.

Wei TT, Lin YC, Lin PH, Shih JY, Chou CW, Huang WJ, Yang YC, Hsiao PW, Chen CC.

Oncotarget. 2015 May 20;6(14):12481-92.

17.

CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.

Kelly WK, Marks P, Richon VM.

Clin Cancer Res. 2015 May 15;21(10):2198-200. doi: 10.1158/1078-0432.CCR-14-2556.

PMID:
25979925
18.

CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.

Bates SE, Robey RW, Piekarz RL.

Clin Cancer Res. 2015 May 15;21(10):2195-7. doi: 10.1158/1078-0432.CCR-14-2555.

PMID:
25979924
19.

Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat.

Falkenberg KJ, Gould CM, Johnstone RW, Simpson KJ.

Sci Data. 2014 Jul 8;1:140017. doi: 10.1038/sdata.2014.17. eCollection 2014.

20.

Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.

Sacco JJ, Kenyani J, Butt Z, Carter R, Chew HY, Cheeseman LP, Darling S, Denny M, Urbé S, Clague MJ, Coulson JM.

Oncotarget. 2015 May 30;6(15):13757-71.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk